Form 4: Zimmer Biomet Executive Van Zuilen Reports Stock Transactions

Wilfred van Zuilen, Group President, EMEA at Zimmer Biomet Holdings, Inc., reports transactions involving common stock and restricted stock units.

Summary

• On March 6, 2024, Wilfred van Zuilen, Group President, EMEA of Zimmer Biomet Holdings, Inc., executed transactions involving the company's stock.
• These transactions included the vesting of 2,163 restricted stock units (RSUs) and the subsequent acquisition of 2,163 shares of common stock.
• Additionally, 260 shares were withheld by the company to cover tax obligations related to the RSU vesting at a price of $125.82 per share.
• Van Zuilen also acquired 191 shares under the Company's Employee Stock Purchase Plan through February 1, 2024.
• Following these transactions, Van Zuilen directly owns 7,167 shares of Zimmer Biomet common stock and 4,323 restricted stock units.

Sentiment

Score: 6

Explanation: The sentiment is neutral. It's a routine disclosure of stock transactions by an executive, reflecting standard compensation practices.

Positives

• The vesting of RSUs indicates a form of compensation and alignment with the company's performance.
• Participation in the Employee Stock Purchase Plan shows confidence in the company's future.

Negatives

• The withholding of shares for tax obligations reduces the net gain from the RSU vesting.

Future Outlook

The remaining RSUs vest in two tranches on March 6, 2025, and March 6, 2026.

Industry Context

This Form 4 filing is a routine disclosure required by the SEC for corporate insiders, providing transparency into their transactions in the company's stock. It's common for executives to receive stock-based compensation, and these filings are a regular occurrence.

Comparison to Industry Standards

• Stock-based compensation is a common practice in the medical device industry, used to align executive incentives with shareholder value.
• Companies like Stryker (SYK) and Medtronic (MDT) also utilize RSUs and stock options as part of their executive compensation packages.
• The vesting schedules and terms of these grants are typically detailed in the company's proxy statements.

Stakeholder Impact

• The transactions have a minimal direct impact on stakeholders.
• They provide transparency into executive compensation and ownership.

Key Dates